Northwest Biotherapeutics (NW Bio) now has 30 clinical trial sites open and recruiting across the U.S. in its ongoing phase II clinical trial of DCVaxR-L immune therapy for Glioblastoma multiforme (GBM), the most lethal form of brain cancer. 

NW Bio has reached this milestone ahead of schedule, as the company had projected to reach it by the end of the first quarter. NW Bio also exceeded its projections in the second, their and fourth quarters of 2011.

The company plans to continue adding clinical trial sites and expects to have at least 40 sites open and enrolling by the end of June.  NW Bio will also continue pursuing its programs in Europe. 

“Together with our recently announced partnership with the American Red Cross, the ongoing expansion of our clinical trial sites is helping to build a broad network to bring DCVax to patients throughout the country,” said Linda Powers, CEO of NW Bio. “We are pleased to see the continuing expansion of interest in DCVax in the medical community.”